PALOMA-2 Study Reveals High Response Rates with Monthly Subcutaneous Amivantamab Combined with Lazertinib in EGFR-Mutated NSCLC
In a significant advancement for the treatment of advanced non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) ...
